Research and development daily Roche published etrolizumab UC two maintenance therapy did not reach the end.

2020.08.11 Research and Development NEWS 100% rehabilitation discharged from hospital! Coagulant pathway inhibitor treatment COVID-19 showed strong efficacy; afatini-oxytinib sequentia treatment for the medium OS for nearly 4 years; Gilead Sciences submitted to the FDA a new drug application for the treatment of COVID-19 ... We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference.
(click on the title, read the original) "Drug Research and Development" Roche released new clinical data for etrolizumab UC Phase III clinical data Two maintenance treatments did not reach the end of the day, Roche Group member Genetek released its research drug etrolizumab on moderate to severe active ulcerative colitis (UC) patients in the series of phase 3 clinical studies of the top line data.
four studies, two etrolizumabs reached the primary endpoint of patient remission as an induced treatment, and two studies evaluating etrolizumab as maintenance therapy failed to reach the primary endpoint, with no significant difference in the proportion of patients who received remission mainly from intraskin injections.
100% recovered and discharged from the hospital! Coagulation pathway inhibitor therapy COVID-19 shows strong efficacy Omeros company recently announced the narsoplimab treatment of COVID-19 acute respiratory distress syndrome patients with a sympathetic drug results.
the study involved six patients with COVID-19 with ARDS, all of who required mechanical aeration before treatment, and all recovered, survived and were discharged after treatment with narsoplimab.
Afatini-Oghitini sequentia treatment for the middle OS for nearly 4 years! Blaenger Ingham recently released a new analysis of lung cancer study GioTag, which showed that in U.S. patients with non-small cell lung cancer (n-129) who were positive for the skin growth factor subject mutation (EGFR M plus) and carried the common drug-resistant mutation T790M, Gil Otrif (afatinib, Afatini) and Tagrisso (Terisha, osimertinib, oghitinib) sequential therapy improves total lifetime (OS), with median OS approaching 4 years (47.6 months).
Microbiome Innovation Therapy reaches a critical Phase 3 clinical endpoint Today, Seres Therapeutics announced that SER-109, a microbiome therapy developed by the company, has achieved positive top-line results in the key Phase 3 clinical trial ECOSPOR III for the treatment of relapsed Streptococcus infections.
study showed that SER-109 caused a significant decrease in the proportion of patients who had a recurrence of CDI within eight weeks of giving the drug compared to a placebo, with results exceeding thresholds previously determined in consultation with the FDA.
13x/AZ Collaboration: Patritumab druxtecan and Tagrisso First Triple Pharmaceuticals for lung cancer recently announced that they are entering a clinical trial with AstraZenecon to evaluate the combined treatment of advanced or metastasis non-small cell lung cancer patients with EGFR mutations in patritumab deruxtecan and Tagrisso.
FDA granted paxalisib rare pediatric disease eligibility for efficacy beyond thymosamine! Recently, Kazia Therapeutics announced that the U.S. FDA has granted paxalisib the right to treat a rare pediatric disease called diffuse endogenetic bridge glial.
(Drug Approval) Gilead Sciences submitted a new drug application for redsivir to the FDA today, Gilead announced that it has submitted a new drug application (NDA) for Veklury (remdesivir), a research antiviral drug used to treat COVID-19 patients, to the FDA.
Putin announced that Russia's first new crown vaccine registered Russian President Vladimir Putin announced that Russia's first new crown vaccine has been approved by the Ministry of Health, his daughter has been the first to be vaccinated.
, Russia's deputy health minister, has previously said the first vaccine will be registered on August 12th and will be given priority to health care workers and the elderly.
Kangfang BioPD-1/VEGF (AK112) was approved by NMPA Clinical Trials on the 11th, Kangfang Biological announced that the company's independently developed dual-specific antibody PD-1/VEGF (AK112) was approved by the State Drug Administration for drug clinical trials, will be further carried out in China for advanced solid tumor phase 1b clinical trials.
FDA grants human skin substitute StrataGraft priority review for treatment of deep II burns Mallinckrodt Corporation recently announced that the FDA has accepted StrataGraft's biopharmaceusity license application, a regenerative skin tissue therapy for the treatment of deep II burns in adult patients.
FDA has granted priority review of the application and has set a target date of February 2, 2021 for prescription drug user fees.
Poxel SA has submitted its first application for the world's first market for a new class of sugar-lowering drug imeglimin, Poxel SA announced that its partner, Remeyou Pharmaceuticals, has submitted a new application in Japan for a new oral anti-sugar drug, imeglimin, to treat type 2 diabetes.
both sides expect imeglimin to go on sale in 2021 after approval.
and yellow medicine Sovantinie are submitted for listing in the United States and Yellow Pharmaceuticals today announced that it has received scientific advice from the European EMA's Human Medicines Committee on the use of Sovantini for the treatment of patients with advanced neuroendocrine tumors.
, in view of the fact that no filing issues have been found, and Yellow Pharmaceuticals plans to submit a new drug listing application to the FDA in 2021 after filing a European listing permit application.
Lianhua Qing plague capsules in the Philippines obtained a market license to Ling Pharmaceuticals issued a notice that received the Philippine Food and Drug Administration approved the issuance of drug registration certificate, approved the company's drug Lianhua Qing plague capsules in accordance with the traditional Philippine plant medicine standard registration.
to date, Lianhua Qing Plague Capsules has been licensed for listing in more than 10 countries and regions, including Hong Kong, Macau and Brazil, Indonesia, Canada, Mozambique, Romania and Thailand.
Lianhua Qing plague capsules by the Kyrgyz food supplement registration certificate 11, Toling Pharmaceuticals issued a notice that the company recently received the Kyrgyz Ministry of Health approved the issuance of food supplement registration certificate, approved the company's products Lianhua Qing plague capsules in accordance with the Kyrgyzstan food supplement standard registration.
will be sold to residents as a food supplement through a network of pharmacies and store counters.
(Research and Development Cooperation) Pharmaceutical Ming Juno and Lyell Immunopharma reached a cooperation to develop secondary T-cell therapy 10, Drug Ming-Juno announced a cooperation agreement with Lyell Immunopharma in China and Southeast Asian countries to develop and commercialized step-by-step T-cell therapy for liver cancer treatment.
.